Talk:Z3220040: Difference between revisions
(Created page with ' ----') |
No edit summary |
||
| Line 1: | Line 1: | ||
---- | |||
Questions from Lab 10 article | |||
What is the background to the existing problem / disease condition??? | |||
'''Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells''' | |||
Mozobil- able to mobilise stem cells from bone marros to blood | |||
- doesnt increase mobility of tumor cells in melonoma patients | |||
Treatment for tumor patients- chemotherapy with autologous stem cell transplantation | |||
Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy | |||
- 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells. | |||
- some patients cannot collected enough sample stem cells | |||
Mozobil and Neupogen (filgrastim) solves the above problem | |||
Neupogen increases stem cell production in bone marrow | |||
Mozobil increases the mobility of stem cells from marrow to blood | |||
- | Faculty of Medicine at the University of Utah conducted the use of above drugs- they utilized patients with proven poor stem cell mobilizers and potentially poor stem cell mobilizers | ||
Found that the majority of patients could produce 2 million stem cells and had successful transplantations | |||
Revision as of 12:40, 8 October 2009
Questions from Lab 10 article
What is the background to the existing problem / disease condition???
Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
Mozobil- able to mobilise stem cells from bone marros to blood
- doesnt increase mobility of tumor cells in melonoma patients
Treatment for tumor patients- chemotherapy with autologous stem cell transplantation
Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy
- 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells.
- some patients cannot collected enough sample stem cells
Mozobil and Neupogen (filgrastim) solves the above problem Neupogen increases stem cell production in bone marrow Mozobil increases the mobility of stem cells from marrow to blood
Faculty of Medicine at the University of Utah conducted the use of above drugs- they utilized patients with proven poor stem cell mobilizers and potentially poor stem cell mobilizers Found that the majority of patients could produce 2 million stem cells and had successful transplantations
